| abstract |
The present invention includes an enteric particle containing acetylsalicylic acid or a pharmaceutically acceptable salt thereof, and an enteric particle containing lansoprazole, a stereoisomer thereof or a pharmaceutically acceptable salt thereof, and the acetylsalicylic acid or a pharmaceutically acceptable salt thereof. The dissolution rate of the acceptable salts is for pharmaceutical compositions with up to 10% in 120 minutes in an eluate at pH 4.0. According to the pharmaceutical composition of the present invention, it is possible to prevent the side effects caused by acetylsalicylic acid, while maintaining the elution uniformity of the active ingredient. |